BRCA1 and ovarian cancer: Moreover, results from Phase IIa testing of Vigil vs. placebo [17,18] and recently from a Phase IIb clinical trial involving newly diagnosed advanced ovarian cancer patients with a BRCA1/2 wild-type genetic profile showed greater clinical benefit, as both relapse-free survival (RFS) and OS were improved [19].